LCTX - Earnings announcements

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member Appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 12, 2026, by

Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements Successfully Demonstrated the High-Scale Production Potential of Our Proprietary AlloSCOPE™ Manufacturing Platform Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss Initiated Manufacturing Scale Research Project in Type 1 Diabetes Treated First-Ever Chronic SCI Patient in OPC1 DOSED Device Safety Study Current Cash and Equivalents E

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. "It ha

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on Nove

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes First Chronic Patient Treated in New Clinical Study of OPC1 in Patients with Subacute and Chronic Spinal Cord Injury Hosted the 3rd Annual SCI Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its second quarter 2025 financial and operating results on Tuesday, August 12, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, August 12, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on August 12, 2025, by di

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di

OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on November 14, 2024, by dialing (800) 715-9871 from the U.S. an

24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program OPC1 Clinical Study Start Up Preparations Ongoing Hosted 2nd Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 fi

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 8, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on August 8th, 2024, by dialing (800) 715-9871 from the U.S. and Ca

Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen® Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting OPC1 Clinical Study Start Up Preparation Underway Received CIRM Grant to Support 2nd Annual SCI Investor Symposium Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therap

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and sh

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on March 7th, 2024, by dialing (800) 715-

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of the Roche Group Additional RG6501 (OpRegen®) Data Presented at 23rd Annual EURETINA Congress and 2023 Eyecelerator Meetings U.S. Patent Issued Covering Manufacturing and Differentiation Process for Retinal Pigment Epithelial (RPE) Cells Company On Track to Submit OPC1 Investigational New Drug Amendment in Q4 2023 Initiated Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics Lineage Cell Therapeutic

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on November 9th, 2023, by dialing (800) 715-9871 from the U.S. an

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group FDA Type B Meeting Response Provides Path for New OPC1 Delivery Device Positive Topline Data Reported from Phase 1 VAC2 Study for the Treatment of NSCLC Lineage Added to Russell 3000® Index Established and Presented 1st Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter ended June 30, 202

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 10, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on August 10th, 2023, by dialing (800) 715-9871 from the U.S. and

Additional RG6501 (OpRegen®) Phase 1/2a Clinical Study Results Presented at ARVO 2023 Enrolling Phase 2a Clinical Study of RG6501 (OpRegen) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group Awarded CIRM Grant to Support 1st Annual Spinal Cord Injury Investor Symposium Signed Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune iPSC Lines Initiated Preclinical Testing of ANP1 for Treatment of Hearing Loss Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating re

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on May 11th, 2023, by dialing (800) 715-9871 from the U.S. and Canada and

Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with GA Secondary to AMD Initiated by Genentech, a Member of the Roche Group Submitted RMAT and Pre-IND Materials to Support OPC1 and VAC2 Programs in Spinal Cord Injury and Oncology, Respectively Launched Two New Cell Therapy Programs for the Treatment of Hearing and Vision Loss Established New R&D Facility and Expanded Existing cGMP Manufacturing Facility Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year ended December 31, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 9, 2023, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2022 financial and operating results and to provide a business update. Interested parties may access the conference call on March 9th, 2023, by dialing (800) 715-9

Appointed Jill Howe as Chief Financial Officer Established New R&D Facility and Expanded Existing cGMP Manufacturing Facility Received Notice of Allowance for Patent Applications Covering Directed Differentiation Methods for Retinal Pigmented Epithelium and Oligodendrocyte Progenitor Cells Cash, Cash Equivalents, and Marketable Securities of $66.4 Million as of September 30, 2022 Expected to Provide Capital Into Q3 2024 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter of 2022. Lineage management will

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 10, 2022, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2022 financial and operating results and to provide a business update. Interested parties may access the conference call by dialing (800) 715-9871 from the U.S. and Canada and should re

Advanced RG6501 (OpRegen®) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Activities to Support Planned Regulatory Interactions for OPC1 and VAC2 Expanded Collaboration with Advanced BioMatrix for HyStem® Cell Drug Delivery Technology Cash, Cash Equivalents, and Marketable Securities of $72.0 Million as of June 30, 2022 Expected to Provide Capital Through Q2 2024 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 2022, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 11, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2022 financial and operating results and to provide a business update. Interested parties may access the conference call by dialing (800) 715-9871 from the U.S. and Canada and (646) 307-1

Reported RG6501 (OpRegen®) Clinical Results at 2022 ARVO Meeting; Outer Retinal Structure Improvement Observed in Five Dry AMD Patients Expanded Pipeline with Two New Cell Therapy Development Programs; Auditory Neurons and Photoreceptors Announced Completion of Enrollment in VAC2 Phase 1 NSCLC Study by Cancer Research UK Cash and Cash Equivalents of $78.1 Million as of March 31, 2022 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter of 2022. Lineage management will host a conference call and webcast t

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2022 financial and operating results on Thursday, May 12, 2022, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2022 financial and operating results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharma

Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen®) in Transaction Worth up to $670 Million Retinal Tissue Restoration and Visual Improvements Reported in Four Patients Treated with RG6501 (OpRegen) for Dry Age-Related Macular Degeneration Non-Clinical Testing Initiated to Support New Delivery Device for OPC1 Clinical Trials Worldwide License Agreement Secured for a Cancer Immunotherapy Product Candidate Based on the Lineage VAC Platform Cash and Cash Equivalents of Approximately $83 Million as of January 31, 2022 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, March 10, 2022, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 10, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2021 financial and operating results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S.

Genentech Will Pay Lineage $50 Million Upfront Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments Conference Call to Discuss Collaboration Planned for 8 a.m. ET Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) wi

OpRegen® Continues to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Performance Testing Underway to Support New Delivery Device for OPC1 Clinical Trials Cash, Cash Equivalents, and Marketable Securities of $65.1 Million Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter 2021. Lineage will host a conference call today at 4:30 p.m. Eastern Time to discuss its third quarter 2021 financial results and to provide a business update. "Lineage's approach is to produce specific type

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2021 financial and operating results on Wednesday, November 10, 2021, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Wednesday, November 10, 2021, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2021 financial and operating results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 8

OpRegen® Continued to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Three Cases of Retinal Tissue Restoration Reported; Longest of Which Has Lasted 3 Years Company Added to Russell 3000® and Russell Microcap® Indexes License Agreement Announced with Immunomic Therapeutics Inc. to Develop New DC-Based Therapeutic New Chief Financial Officer Appointed Cash and Marketable Securities of $68.7M Expected to Support Operations Well Into 2023 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 12, 2021, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 12, 2021, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2021 financial and operating results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6